Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

RegulatoryPain ManagementAnalgesicRegulatory Approval

FDA Approval Letter for Tramadol Hydrochloride by Sun Pharma

The FDA's approval of Tramadol Hydrochloride by Sun Pharma is significant as it strengthens their position in the competitive analgesic market. This development necessitates a review of market strategies by other companies in the pain management sector to mitigate potential impacts on market share and pricing.

Published: June 29, 2026
Updated: June 29, 2026
Author: Humanexa Intelligence
Therapeutic area: Pain Management / Analgesic
Company: Sun Pharma
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Company

Sun Pharma

Asset

FDA

Indication

Pain Management / Analgesic

Status

Approved

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

The FDA's approval of Tramadol Hydrochloride by Sun Pharma is significant as it strengthens their position in the competitive analgesic market. This development necessitates a review of market strategies by other companies in the pain management sector to mitigate potential impacts on market share and pricing.

Why it matters

The FDA's approval of Tramadol Hydrochloride by Sun Pharma is significant as it strengthens their position in the competitive analgesic market. This development necessitates a review of market strategies by other companies in the pain management sector to mitigate potential impacts on market share and pricing.

What changed

Regulatory Approval

Analysis

The FDA has issued an approval letter for the ANDA076100 application for Tramadol Hydrochloride submitted by Sun Pharma.

The FDA's approval of Tramadol Hydrochloride by Sun Pharma is significant as it strengthens their position in the competitive analgesic market. This development necessitates a review of market strategies by other companies in the pain management sector to mitigate potential impacts on market share and pricing.

Monitor for market entry timelines and any competitive responses from other analgesic manufacturers.

Related companies & assets

Companies

  • Sun Pharma →

Assets

  • FDA →
  • Tramadol Hydrochloride →

Sources & Humanexa intelligence

Source links

  • FDA Approval Letter for Tramadol Hydrochloride by Sun Pharma ↗

Related Humanexa pages

  • FDA Approval Letter for Tramadol Hydrochloride by Sun Pharma →

Related signals

Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Company

IC-GREEN

Asset

FDA

Indication

Ophthalmology / Diagnostic Imaging

Status

Approved

Signal Score

8.2

Regulatoryhigh signal

FDA Accepts Supplement Application for IC-GREEN by RENEW PHARMS

The FDA has accepted a supplemental application for IC-GREEN, an imaging agent containing Indocyanine Green, submitted by RENEW PHARMS.

July 5, 2026Read signal →
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Company

Impax Labs

Asset

Impax

Indication

Neurology / ADHD

Status

Approved

Signal Score

8.2

Regulatoryhigh signal

Impax Labs Receives AP for Methylphenidate Hydrochloride ANDA205105

Impax Labs has received an Abbreviated Approval (AP) for its ANDA205105 application for Methylphenidate Hydrochloride.

July 5, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.